A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers
about
Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterusPharmacology and clinical applications of selective estrogen receptor modulators.Fulvestrant for the treatment of endometrial cancer.Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report.Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.Role of fulvestrant in the management of postmenopausal breast cancer.Hormonal therapy in gynecological sarcomas.Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs.The role of fulvestrant in endometrial cancer.Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer.Inhibition of Estrogen Signaling Reduces the Incidence of -associated Mammary Tumor Formation
P2860
Q24800866-FFC57688-B5FB-4504-92F8-80AE2026E993Q33384192-EAC71B06-1B07-4468-91C0-387FFC8BB5E1Q34514391-00A907E1-D564-42CB-8982-D3F6D8A7EFB8Q34626963-B7CC2744-9C0E-4563-934E-D5C24A4BB1FCQ35142182-6441911F-1F3D-48A0-ABAA-9395113595F9Q35750078-E96FE351-728D-408B-92E5-0D29010A3AC5Q36185614-7E20B97B-0196-4FEC-9DBC-08C184F75385Q36297937-53A12BC7-C64E-4386-8C60-9CF640DF512BQ36517144-1B028305-03BA-4B51-93A2-54BF1120DFB5Q36540703-1E38C2E0-B38A-4254-82DB-D6CBAE20B367Q36567154-9593941B-51E1-47C4-97ED-DBC299B32A65Q37532641-F02943A4-7A1C-4E18-AEE6-4A7E0CF9730EQ37952234-E4DBE2CE-0B8A-4231-96B9-AA57E94907D5Q38030590-54FB6A56-3233-4F41-8F47-3EE22EAB9CE9Q38107969-607D7691-304F-494D-9844-882A1551D0E2Q38970776-7F0C814C-9FC0-441B-BAD6-6C2FAB3CF1C0Q39090350-E7A23B72-8FB4-47B8-B410-2E248627B2EDQ40464404-06A6FAF7-374E-433C-AC43-4850A7A235E5Q58786210-872A5C3B-9813-410F-A54A-397C8ADCAC0B
P2860
A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
A phase I trial to assess the ...... lthy postmenopausal volunteers
@ast
A phase I trial to assess the ...... lthy postmenopausal volunteers
@en
type
label
A phase I trial to assess the ...... lthy postmenopausal volunteers
@ast
A phase I trial to assess the ...... lthy postmenopausal volunteers
@en
prefLabel
A phase I trial to assess the ...... lthy postmenopausal volunteers
@ast
A phase I trial to assess the ...... lthy postmenopausal volunteers
@en
P2093
P2860
P356
P1476
A phase I trial to assess the ...... lthy postmenopausal volunteers
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600644
P407
P577
2002-12-01T00:00:00Z